Nucleoside/nucleotide reverse transcriptase inhibitor sparing regimen with once daily integrase inhibitor plus boosted darunavir is non-inferior to standard of care in virologically-suppressed children and adolescents living with HIV – Week 48 results of the randomised SMILE Penta-17-ANRS 152 clinical trial

Authors:

Abstract
No abstract available
Funding Information
  • Institut National de la Santé et de la Recherche Médicale
  • Gilead Sciences
  • Agence Nationale de Recherches sur le Sida et les Hépatites Virales
  • Janssen Pharmaceutica
  • Medical Research Council

This publication has 22 references indexed in Scilit: